Navigation Links
BHR Pharma Statement on Brain Injury Awareness Month - Better Awareness, Treatment, Research Needed Now
Date:3/23/2010

HERNDON, Va., March 23 /PRNewswire-USNewswire/ -- Julian Bailes, MD, BHR Pharma, LLC's Lead Advisor for Moderate Traumatic Brain Injury (TBI) today released the following statement regarding Brain Injury Awareness Month:

"BHR Pharma salutes the Brain Injury Association of America (BIAA) for its concerted efforts to raise awareness about the dangers and proper treatment of concussions everywhere from playgrounds to professional sports arenas.  BIAA is correctly pointing out through its advocacy that concussions are TBIs, with the potential for serious, debilitating and long-term effects.  

"TBI is defined as a non-degenerative, non-congenital insult to the brain from an external mechanical force, possibly leading to temporary or permanent impairments of cognitive, physical and psychosocial functions with an associated diminished or altered state of consciousness.

"According to the Centers for Disease Control and Prevention, U.S. hospital emergency departments treat an estimated 3.8 million sports- and recreation-related concussions annually.  It is time that athletes of all ages and their coaches completely move away from 'play through pain' attitudes in relation to concussions.  

"During Brain Injury Awareness Month, it is also important to recognize that traumatic brain injuries range from concussions to severe head trauma, such as injuries sustained in traffic accidents – a leading cause of TBI in the world, accounting for 40-50 percent of hospitalizations.  Approximately 1.7 million Americans per year suffer a traumatic brain injury, resulting in 52,000 deaths, 275,000 hospitalizations and 80,000 cases of long-term disability.

"Although the prognosis for patients that are hospitalized with a severe form of TBI is generally not very promising, current research is pointing to a future of treatment that potentially offers these patients and their families hope for better quality of life.  In particular, two multi-center, Phase 3 clinical trials are worth noting.  They are BHR Pharma's SyNAPSe (http://www.synapse-trial.com/) and Emory University's ProTECT III (http://em.emory.edu/protect/) trials.  Both are evaluating the safety and effectiveness of progesterone as a neuroprotective agent for treating moderate to severe TBI.

"The success of these studies requires that study staff quickly reach family members to request permission to enroll their loved one in the trial. Although it may occur at a time of great personal pain and confusion, the families' difficult decision-making – usually in an emergency room setting – will go a long way in helping advance TBI treatment."

SOURCE BHR Pharma, LLC

Back to top

RELATED LINKS
http://www.synapse-trial.com
http://em.emory.edu/protect/

'/>"/>

SOURCE BHR Pharma, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program
2. Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance
3. Octapharma Accepting Applications for Research Grants Through March 31
4. Two Long-Term Care Organizations Select Remedi SeniorCare for Pharmacy Services
5. Possible pharmacological target(s) identified in pediatric OSA
6. Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
7. Six Key Areas of Learning for Pharmaceutical and Healthcare Marketing in 2010
8. Frost & Sullivan Ghanaian Pharmaceutical Industry Innovation & Advancement Award Conferred on LaGray Chemical Company
9. Viscira Expands Interactive Solutions to Reduce Marketing Expenses for Pharmaceutical Companies in Challenging Economic Times
10. Nutra Pharma Announces Fourth Quarter Sales for its Over-the-Counter (OTC) Pain Reliever, Cobroxin
11. Pharmalink Regulatory Affairs Consulting Firm Opens New Offices in Washington, DC and Hartford, CT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
Breaking Medicine Technology: